Search research articles
Contact Us
Filters
Showing results (41-50 of 45) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 45 results.
Cancer Research
|
March 1, 1990
Purine metabolism of human glioblastoma in vivo
K Pillwein, P Chiba, A Knoflach, et al.
Journal of Medicinal Chemistry
|
November 22, 1996
Structure-activity relationship studies on benzofuran analogs of propafenone-type modulators of tumor cell multidrug resistance
G Ecker, P Chiba, M Hitzler, et al.
International Journal of Cancer
|
August 19, 1993
Cytotoxicity, differentiating activity and metabolism of tiazofurin in human neuroblastoma cells
K Pillwein, K Schuchter, G Ressmańn, et al.
Biochemical Pharmacology
|
April 21, 2007
Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24)
P Heffeter, M A Jakupec, W Körner, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 28, 2004
Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A)
P Heffeter, M Pongratz, E Steiner, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 45) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 45 results.
Cancer Research
|
March 1, 1990
Purine metabolism of human glioblastoma in vivo
K Pillwein, P Chiba, A Knoflach, et al.
Journal of Medicinal Chemistry
|
November 22, 1996
Structure-activity relationship studies on benzofuran analogs of propafenone-type modulators of tumor cell multidrug resistance
G Ecker, P Chiba, M Hitzler, et al.
International Journal of Cancer
|
August 19, 1993
Cytotoxicity, differentiating activity and metabolism of tiazofurin in human neuroblastoma cells
K Pillwein, K Schuchter, G Ressmańn, et al.
Biochemical Pharmacology
|
April 21, 2007
Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24)
P Heffeter, M A Jakupec, W Körner, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 28, 2004
Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A)
P Heffeter, M Pongratz, E Steiner, et al.
Page
of 5